| HOME >> MEDICINE >> TECHNOLOGY |
$
250$
2Other expanded access program income, net
1,3511,927Total revenues
1,6011,929Operating expenses:Research and development
5,760642Selling, general and administrative
3,2561,538Total operating expenses
9,0162,180Operating loss
(7,415)(251)Investment income
527397Interest expense
(4)(28)Income (loss) before taxes
(6,892)118Income tax expense
2-Net (loss) income
(6,894)118Less: accretion of beneficial conversion feature
(9,175)-Net (loss) income attributable to common stockholders
$
(16,069)$
8Basic and diluted net (loss) income attributable tocommon stockholders per common share
$
(0.85)$
.01Weighted average basic common shares outstanding
18,81413,021Weighted average diluted common shares outstanding
18,81413,055INSMED INCORPORATEDConsolidated Statements of Cash Flows (Unaudited)(in thousands) Three Months Ended March 31,20112010Operating activitiesNet (loss) income $
(6,894)$
8Adjustments to reconcile net (loss) income to net cash(used in) provided by operating activities:Depreciation and amortization7525Stock based compensation expense16765Changes in operating assets and liabilities: Accounts receivable30256 Prepaid expenses10877 Accounts payable1,632121 Accrued expenses(341)(309) Deferred revenue(158)79 Interest payable-(1)Net cash (used in) provided by operating activities(5,109)231Investing activities Purchase of fixed assets(14)- Sales of short-term investments 16,58826,393 Purchases of short-term investments (87)(19
'/>"/>
| SOURCE Insmed Incorporated Copyright©2010 PR Newswire. All rights reserved |